Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 910 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: morphine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intrathecal Hydromorphone for Pain Control After Cesarean Section

NCT02096003
View directory record Official record
Conditions
Pain, Cesarean Section
Interventions
Intrathecal morphine, Intrathecal hydromorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

NCT04410978
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 7:18 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of the Post-C/S Analgesic Effects of Neuraxial Duramorph vs Bilateral TAP Block With Liposomal Bupivacaine

NCT03638011
View directory record Official record
Conditions
Caesarean Section
Interventions
Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Titration of Intravenous Hydromorphone

NCT01892709
View directory record Official record
Conditions
Acute Severe Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 18, 2026, 7:18 AM EDT
Not listed Phase 3 Interventional

Femoral Nerve Block Compared to Exparel in Total Knee Replacement

NCT02473198
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Exparel, Femoral Nerve Block Bupivacaine, Toradol, Morphine Sulfate
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
18 Years to 73 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 18, 2026, 7:18 AM EDT
Recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Incidence of Headache Following an Unintentional Dural Puncture

NCT01977898
View directory record Official record
Conditions
Postdural Puncture Headache, Post-Lumbar Puncture Headache, Cerebrospinal Fluid Leaks
Interventions
Morphine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 18, 2026, 7:18 AM EDT
Enrolling by invitation Phase 4 Interventional

Prospective Opioid-Free AIS Fusion

NCT06935331
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Opioid-Free/Opioid-Avoidant, Opioid-Containing
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 18, 2026, 7:18 AM EDT
Terminated Phase 4 Interventional Results available

Two Dose Epidural Morphine for Post-cesarean Analgesia

NCT01844206
View directory record Official record
Conditions
Pain, Morphine Adverse Reaction
Interventions
Epidural Morphine, Epidural Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Not applicable Interventional Results available

Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery

NCT00804609
View directory record Official record
Conditions
Epidural Analgesia, Obstetric
Interventions
DepoDur following epidural lidocaine, DepoDur following spinal anesthetic
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

Masked Faces in Parkinson Disease: Mechanism and Treatment

NCT00350402
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Respiratory muscle strength training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 18, 2026, 7:18 AM EDT
Active, not recruiting Not applicable Interventional

Efficacy of Virtual Warrior Renew Therapy for Veterans Who Experienced Military Sexual Trauma

NCT05776719
View directory record Official record
Conditions
Military Sexual Trauma (MST), Post Traumatic Stress Disorder
Interventions
Health & Wellness, Warrior Renew
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

NCT05093322
View directory record Official record
Conditions
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Interventions
Surufatinib in combination with Gemcitabine
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
2 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 18, 2026, 7:18 AM EDT
Completed No phase listed Observational

Multicenter Perioperative Opioid Pharmacogenetic Study

NCT01495611
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 18, 2026, 7:18 AM EDT
Recruiting Not applicable Interventional

Short Title: Standard vs. Lower Pressure Pneumoperitoneum

NCT06338865
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Carbon dioxide, Bupivacaine, Oxycodone
Other · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

NCT02462811
View directory record Official record
Conditions
Pain, Nausea, Vomiting
Interventions
CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Drug
Lead sponsor
Joseph Hazelton
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 18, 2026, 7:18 AM EDT
Recruiting No phase listed Observational

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Interventions
Ublituximab
Drug
Lead sponsor
Neurology Center of New England P.C.
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 18, 2026, 7:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 18, 2026, 7:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Decision Support to Improve System Naloxone Co-prescribing

NCT06271668
View directory record Official record
Conditions
Medication Abuse, Harm Reduction, Opioid Overdose, Opioid Prescribing
Interventions
Naloxone Co-prescribing Clinical Decision Support (CDS)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 89 Years
Enrollment
114,272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 18, 2026, 7:18 AM EDT
Withdrawn Phase 3 Interventional

Pain Control Without Opioids

NCT04813991
View directory record Official record
Conditions
Perioperative Pain
Interventions
Ibuprofen 600 mg, OxyCODONE 5 Mg Oral Capsule
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 18, 2026, 7:18 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction

NCT03105518
View directory record Official record
Conditions
Oocyte Retrieval, Postoperative Pain
Interventions
Fentanyl, Acetaminophen, Oxycodone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 7:18 AM EDT